Median Survival Time - an overview | ScienceDirect Topics
Survival Analysis
Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram
Survival Analysis in R
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Finding median survival time from survival function - Cross Validated
Opdualag™ (nivolumab and relatlimab-rmbw) Efficacy in Melanoma
a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Survival (time to event) data: median survival times | The BMJ
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
The overall survival did not reach median. The median progression free... | Download Scientific Diagram
a Kaplan–Meier survival curve with a median follow-up time of... | Download Scientific Diagram
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
primed.info
Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
